Derepression of human endogenous retrovirus and implications for immunotherapy for clear cell renal cell carcinoma
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210096
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $347,100
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $347,100 project grant to Dana-Farber Cancer Institute, Inc. doing business as Dfci, for the period of March 1, 2022 through February 28, 2025. The grant supports research entitled "Derepression of Human Endogenous Retrovirus and Implications for Immunotherapy for Clear Cell Renal Cell Carcinoma" under the Military Medical Research and Development program.
This project will investigate medical solutions for clear cell renal cell carcinoma through basic, applied, and advanced biomedical research focused on derepression of human endogenous retrovirus and implications for immunotherapy. The research aims to transform healthcare for service members and the public by developing innovative and impactful medical solutions applicable to both battlefield wounds and cancer treatment.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $347,100 |
Quick answers
Who received award W81XWH2210096?
W81XWH2210096 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on March 1, 2022.
How much is award W81XWH2210096 worth?
$347,100 has been obligated on W81XWH2210096.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award